Phase 2
N=13
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL Amyloidosis
Bottom Line
View on ClinicalTrials.gov: NCT04304144 ↗Enrolled (actual)
13
Serious AEs
44.7%
Results posted
Mar 2025
Primary outcome: Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment Discontinuation — 4; 3; 6; 13 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- CAEL-101 (Drug); SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) (Drug); Daratumumab (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment Discontinuation |
4; 3; 6; 13; 12; 0 | — |
| PRIMARY Number of Participants With Dose-limiting Toxicity (DLT) During the First 4 Weeks of Therapy |
0; 0; 0; 0 | — |
| SECONDARY Maximum Observed Plasma Concentration (Cmax) of CAEL-101 |
126; 255; 244; 280; 580; 552 | — |
| SECONDARY Area Under Plasma Concentration-time Curve Over Dosing Interval (AUCtau) of CAEL-101 |
14400; 27600; 28600; 29400; 147000; 139000 | — |
Summary
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability of CAEL-101 in combination with the standard of care (SoC) cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab .
Eligibility Criteria
Key Inclusion Criteria
Each patient must meet the following criteria to be enrolled in this study.
- AL amyloidosis Mayo stage I, II or IIIa
- For Part A only, measurable hematologic disease defined by at least one of the following:
- involved/uninvolved free light chain difference (dFLC) > 5mg/dL or
- free light chain (FLC) > 5mg/dL with abnormal Kappa/Lambda ratio or
- serum protein electrophoresis (SPEP) m- spike > 0.5 g/dL Patients with confirmed AL amyloid diagnosis without measurable disease may be enrolled with consultation and approval by the Sponsor Medical Monitor or their designee.
- a. For Part A, currently on and continuing OR planned to start concurrent chemotherapy with CyBorD administered weekly as SoC. b. For Part B, currently on and continuing OR planned to start concurrent chemotherapy with CyBorD and daratumumab administered as SoC.
Key Exclusion Criteria
Patients who meet any of the following criteria will not be permitted entry to the study.
- Any form of secondary, hereditary, senile, localized, dialysis-related or leukocyte chemotactic factor 2-related (ALECT2) amyloidosis
- Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma. Patients with signs and/or symptoms attributable ONLY to amyloidosis and who do NOT meet IMWG definition of smoldering myeloma may be enrolled upon approval of the medical monitor.
- Supine systolic blood pressure 20 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion
- Receiving dialysis
- Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or percutaneous cardiac intervention with recent stent, coronary artery bypass grafting or major cerebrovascular accident within 6 months prior to screening
- Left ventricular ejection fraction (LVEF) < 45 percent by echocardiogram or multigated acquisition scan (MUGA)
Data sourced from ClinicalTrials.gov (NCT04304144). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.